HCAR2 Polyclonal Antibody
€0.00
In stock
SKU
ELK-ES11652
Catalog Number: ELK-ES11652
Reactivity: Human
Applications: WB, ELISA
Information
Request Manual ELK-
Questions? Contact us!
Reactivity: Human
Applications: WB, ELISA
Information
Request Manual ELK-
Questions? Contact us!
Background:
developmental stage:Expression in neutrophils occurs in the late terminal differentiation phase.,function:Acts as a high affinity receptor for both nicotinic acid (also known as niacin) and (D)-beta-hydroxybutyrate and mediates increased adiponectin secretion and decreased lipolysis through G(i)-protein-mediated inhibition of adenylyl cyclase. This pharmacological effect requires nicotinic acid doses that are much higher than those provided by a normal diet. Mediates nicotinic acid-induced apoptosis in mature neutrophils. Receptor activation by nicotinic acid results in reduced cAMP levels which may affect activity of cAMP-dependent protein kinase A and phosphorylation of target proteins, leading to neutrophil apoptosis.,miscellaneous:The rank order of potency for the displacement of nicotinic acid binding is 5-methyl pyrazole-3-carboxylic acid = pyridine-3-acetic acid > acifran > 5-methyl nicotinic acid = acipimox >> nicotinuric acid = nicotinamide.,similarity:Belongs to the G-protein coupled receptor 1 family.,tissue specificity:Expression largely restricted to adipose tissue and spleen. Expressed on mature neutrophils but not on immature neutrophils or eosinophils.,
Immunogen: Synthesized peptide derived from human protein . at AA range: 260-340
Isotype: Rabbit
Purification: The antibody was affinity-purified from rabbit antiserum by affinity-chromatography using epitope-specific immunogen.
Concentration: 1 mg/ml
Observed band: 39
GeneID: HCAR2 GPR109A HCA2 HM74A NIACR1
Storage: -20°C/1 year
NOTE: For Research Use Only
developmental stage:Expression in neutrophils occurs in the late terminal differentiation phase.,function:Acts as a high affinity receptor for both nicotinic acid (also known as niacin) and (D)-beta-hydroxybutyrate and mediates increased adiponectin secretion and decreased lipolysis through G(i)-protein-mediated inhibition of adenylyl cyclase. This pharmacological effect requires nicotinic acid doses that are much higher than those provided by a normal diet. Mediates nicotinic acid-induced apoptosis in mature neutrophils. Receptor activation by nicotinic acid results in reduced cAMP levels which may affect activity of cAMP-dependent protein kinase A and phosphorylation of target proteins, leading to neutrophil apoptosis.,miscellaneous:The rank order of potency for the displacement of nicotinic acid binding is 5-methyl pyrazole-3-carboxylic acid = pyridine-3-acetic acid > acifran > 5-methyl nicotinic acid = acipimox >> nicotinuric acid = nicotinamide.,similarity:Belongs to the G-protein coupled receptor 1 family.,tissue specificity:Expression largely restricted to adipose tissue and spleen. Expressed on mature neutrophils but not on immature neutrophils or eosinophils.,
Immunogen: Synthesized peptide derived from human protein . at AA range: 260-340
Isotype: Rabbit
Purification: The antibody was affinity-purified from rabbit antiserum by affinity-chromatography using epitope-specific immunogen.
Concentration: 1 mg/ml
Observed band: 39
GeneID: HCAR2 GPR109A HCA2 HM74A NIACR1
Storage: -20°C/1 year
NOTE: For Research Use Only
| Is Featured? | No |
|---|
Write Your Own Review